1. Introduction {#s0005}
===============

The movement and insertion of retrotransposable elements across the genome causes mutation that may result in large-scale alterations in gene expression and regulation. With their ability to introduce new splice sites, promoters, and regulatory elements into a locus, active retrotransposition is a driving force for genomic diversity ([@bb0040], [@bb0065]), and is likely to have contributed to the species- and tissue-specific expression patterns that we see in primates and humans ([@bb0200]). While they are often referred to as "jumping genes", the majority of retrotransposable elements have over time lost their ability to mobilise ([@bb0030], [@bb0170]). However, they still contain many elements that are capable of conferring regulatory properties and may influence the genetic architecture and function at the surrounding loci. In this regard, retrotransposable elements can be considered as genetic elements that may impact the regulation of nearby genes, regardless of any further retrotransposition events. It is in this context that they will herein be considered, and we highlight the importance of these elements in relation to genes of interest discussed by groups at the Aberdeen Neuropeptide Conference 2015, in particular the AVP/Oxytocin locus, as well as the tachykinin receptor TACR3, and voltage gated ion channels TRPV1/V3.

2. Overview of transposable elements {#s0010}
====================================

Transposable elements (TEs) make up approximately half of the human genome ([@bb0155]), and are broadly divided into two categories, named class I and class II, based on their method of replication via a DNA or RNA intermediate. Class II elements include DNA transposons, which make up around 2% of our genome, and are known to have been mobilised as DNA through a cut-and-paste mechanism before losing their ability to mobilise in the human lineage ([@bb0035], [@bb0095]).

Alternatively, class I TEs are mobilised and inserted through a two-step process that first involves transcription from the DNA sequence to produce an RNA intermediate. This RNA intermediate is then reverse transcribed into DNA and inserted into a new position in the genome. Class I TEs can be further divided into LTR and non-LTR families, based on the presence or absence of long terminal repeats (LTRs) within the element sequence. LTR retrotransposons include human endogenous retroviruses (HERVs), which make up around 8% of our genome and function in gene regulation, often encoding alternative promoters, resulting in tissue-specific expression ([@bb0015]).

Non-LTR retrotransposons include Long Interspersed Nuclear Elements (LINEs), Short Interspersed Nuclear Elements (SINEs), and SINE-VNTR-Alus (VNTR = Variable Number Tandem Repeat; SVAs), and are known to be the most abundant class of mobile element in the human genome. While the majority of transposable elements have become inactive throughout the course of evolution, non-LTR retrotransposons are the only group that are known to remain mobile and active within the human lineage ([@bb0170]).

SVAs are the most recently evolved family of active non-LTR retrotransposable elements, being present only in the hominid genomes, with approximately 2700--3000 SVA copies in humans ([@bb0155], [@bb0210]). These non-autonomous elements contain consensus sequences for LINE-1 endonuclease recognition, and rely directly on active expression of the LINE-1 machinery, ORF1p and ORF2p, in order to be mobilised in *trans* ([@bb0100], [@bb0190]).

The SVA family of transposable elements can be further divided into 7 subfamilies, named A -- F1 in order of age. SVA A is the oldest subfamily in evolutionary terms (\~ 13.6 Myrs) and SVA E, F (\~ 3.5 and \~ 3.2 Myrs, respectively), and F1 the youngest, whilst subfamilies D and B are the most abundant in the genome, accounting for \~ 40% and \~ 15% of the total number of SVA elements. The youngest subfamilies, SVA E, F, and F1, are human specific, and along with SVA D (\~ 9.6 Myrs), are the only subfamilies that remain polymorphic within the human population ([@bb0250]).

Structurally, a canonical SVA is comprised of 5 main components ([Fig. 1](#f0005){ref-type="fig"}), beginning with (1) a simple hexamer repeat of (CCCTCT)n at the 5′ end, which may be variable in copy number, followed by (2) an Alu-like region made up of two antisense Alu fragments separated by a region of intervening sequence, (3) one or two variable number tandem repeat (VNTR) regions, typically with a repeating sequence between 35 and 50 bp, (4) a SINE region derived from the 3′ LTR of the retroviral HERV-K10 element, and finally (5) a 3′ poly-A signal ([@bb0250]). The seventh SVA family, known as F1, lacks the 5′ CCCTCT hexamer repeat, instead containing a 5′ transduction of exon 1 of the MAST2 gene ([@bb0005]).Fig. 1Schematic of a canonical SVA structure showing the five key domains, beginning with a 5′ repeat of the CCCTCT hexamer, followed by an Alu-like structure. The middle of the SVA contains a region of variable number tandem repeats (VNTRs), with older SVAs containing one, and younger SVAs containing two tandem repeat regions. A SINE-R region follows the VNTR, and a poly-A tail marks the 3′ end of the SVA.Fig. 1

3. SVAs as regulatory elements {#s0015}
==============================

Over 60% of SVAs in the human genome are located in genes, or within 10 kb of their flanking sequence ([@bb0210]). SVAs are known to be enriched at high GC and gene dense regions, which may suggest preferential insertion in areas such as promoters and actively transcribed regions ([@bb0250]). SVAs themselves are generally around 60% GC, with this potentially exceeding 70% within the VNTR region ([@bb0250]). The definition of a CpG island is a sequence over 200 bp with a GC content exceeding 50% and an observed-to-expected CpG ratio over 60%. As such, SVAs may be simplistically thought of as mobile CpG islands ([@bb0225]). Indeed, the first exon of MAST2, which has been incorporated into the SVA F1 structure through a 5′ transduction, is defined as a CpG island and has been confirmed to act as a positive transcriptional regulator in human germline cells ([@bb0270]). In this way, SVAs may positively or negatively regulate expression of nearby genes by recruiting transcription factors or altering local chromatin structure depending on epigenetic marks across the element, as has been demonstrated for human endogenous retroviruses ([@bb0075]), causing a region to become either accessible or inaccessible to transcriptional machinery. It is known that retrotransposable elements become hypomethylated in disease states such as cancer ([@bb0010], [@bb0175]), where primate-specific retrotransposons are preferentially affected ([@bb0230]), and some retrotransposons become hypomethylated during human ageing ([@bb0165], [@bb0120], [@bb0025]). Thus, changes in epigenetic marks across SVAs resulting in, for example, inappropriate reactivation of the element, may contribute to dysregulation of nearby genes and their related pathways, as has been demonstrated for LINE-1 elements in cancer ([@bb0115]).

Due to their high GC content, SVAs may also be capable of forming alternative DNA structures which affect transcription, such as G-quadruplexes (G4) ([@bb0130]). G4 structures form in regions containing multiple short runs of G bases, which form planar tetrad structures through Hoogsteen hydrogen bonding and stack together to form helices ([@bb0195]). Over 40% of human genes contain one or more potential G4 sequences in their promoter region ([@bb0110]), and mutation or stabilisation of the G4 structure has been shown to modify gene expression both *in vitro* and *in vivo* ([@bb0050], [@bb0220], [@bb0080], [@bb0255])*.* Through sequence analysis, our group have shown that despite accounting for only 0.13% of the total genome, SVAs make up nearly 2% of DNA across the genome that is predicted to form G4 structures. In particular, the 5′ CCCTCT hexamer repeat in SVAs is likely to be the most amenable to G4 formation, and, when accounting for their size, SVAs have the greatest contribution to G4 DNA out of all other genetic elements ([@bb0210]). As the evolutionary age of the SVA subtypes decreases, the percentage of sequence capable of quadruplex formation is increased, giving the human-specific SVA E, F, and F1 subtypes the most potential to form transcriptional modulatory G4 structures. This is due in part to the increased copy number of the CCCTCT hexamer repeat in younger SVA subtypes, and also to the increase in VNTR potential to form quadruplex, as the younger subtypes contain two VNTRs with a higher GC content, as opposed to one with lower GC content in the older SVAs. For example, the SVA F1 subtype lacks the 5′ hexamer, and thus its G4 potential is conferred entirely by the high GC VNTR regions ([@bb0210]).

We have demonstrated the regulatory properties of both full length SVAs as well as their individual components using reporter gene constructs both *in vitro* and *in vivo*, in cell lines and chick embryo models ([@bb0210], [@bb0215]). For example, the Parkinson\'s related gene, PARK7, has a full length human-specific SVA D located approximately 8 kb from the major transcriptional start site. Reporter gene experiments showed that the PARK7 SVA can positively modulate expression *in vitro*, with a truncation lacking the SINE domain showing the greatest enhancer capability. Individually, the tandem repeat region of this SVA acted as a negative regulator of transcription, identifying a range of modulatory effects conferred by the distinct elements in this composite structure ([@bb0210]). Similarly, our analysis of the primate-specific SVA D, which lies 10 kb upstream of the FUS gene, verified the regulatory properties of this SVA *in vivo* using a chick embryo model. Again, different components of the SVA displayed different regulatory properties, with the central VNTR region acting as a positive transcriptional regulator, whereas the complete SVA acted to decrease reporter gene expression. GFP imaging studies in the chick embryo revealed activity of the FUS SVA in the developing neural tube ([@bb0215]).

Kim et al. have also demonstrated the capacity of SVAs to act as novel promoters through bioinformatic analysis of human-specific insertions that are expressed as exons in the transcriptome. Although this analysis would not capture SVAs acting as more distant regulators, Kim et al. identified 12 cases in which human-specific SVA insertions led to the formation of novel promoters, driving expression of human-specific transcripts originating from within the SVA ([@bb0145]). For example, an SVA insertion 5′ to the TBPL2 gene has been shown to act as a novel promoter for a human-specific transcript of TBPL2, in which SVA derived sequence is included as a novel first exon. Similarly, an SVA insertion at intron 19 of the WDR66 gene resulted in expression of a human-specific truncated isoform of WDR66, containing exons 20--22 ([@bb0145]). SVA insertions have also been shown to drive expression of novel antisense transcripts, including a human-specific SVA insertion at intron 45 of the SYNE2 gene, which acts as a novel promoter for the expression of six antisense ESTs ([@bb0140]).

Multiple components of the SVA composite structure are known to regulate neuropeptide gene expression individually. VNTRs, which are a major component of SVAs, have been demonstrated to be key neuropeptide regulatory domains. For example, the arginine vasopressin 1a receptor (AVPR1A) contains two upstream VNTRs named RS1 and RS3. These repetitive regions were originally identified in the prairie vole, and polymorphisms were found to be associated with monogamous and non-monogamous behaviour between different species ([@bb0090], [@bb0085]). Tansey et al. have demonstrated the allele-specific regulatory effects of both repetitive regions, with the long alleles of both the RS1 and RS3 supporting increased transcription of a reporter gene over the shorter alleles in the SH-SY5Y neuroblastoma cell line ([@bb0235]). Further studies have shown that differences in tandem repeat number at the promoter of AVPR1A contributes to differences in tissue-specific expression, resulting in species-specific receptor distribution across the brain and contributing to behavioural diversity ([@bb0060]). In humans, variation at the AVPR1A RS1 and RS3 has been associated with differences in behavioural traits such as pair bonding ([@bb0245]). Variation at these regions is known to interact with environmental factors such as childhood adversity to mediate social behaviour in adulthood ([@bb0160]), and has been shown to correlate with autism spectrum behaviour in Finnish and Korean populations ([@bb0125], [@bb0265]).

Similarly, expression of the POMC gene in both the human and mouse hypothalamus is co-ordinated by the action of two distal regulatory elements, named nPE1 and nPE2, which act as neuronal enhancers ([@bb0055]). By comparing genomes from multiple species, Santangelo et al. demonstrated that nPE2 originated from a SINE retrotransposon insertion at this locus in the evolutionary lineage leading to mammals, thereby conferring distinct regulatory properties to the mammalian POMC gene in hypothalamic neurons ([@bb0205]). Kuehnen et al. have also demonstrated the regulatory effects of Alu element insertion into the POMC gene through evolution. The human intron 2 of POMC contains three Alu insertions and the CpG island at this region is hypermethylated. A similar pattern of hypermethylation at this region is seen in chimpanzees, who also have Alu insertions at the POMC intron 2. However, in the mouse and in more distant primates such as lemurs, no Alu insertions are present in POMC intron 2 and consequently little to no methylation is found across this region. This suggests that the insertion of retrotransposons into this neuropeptide gene through evolution has resulted in species-specific methylation patterns which are likely to result in altered expression of POMC in higher primates ([@bb0150]).

As SVA are composite structures which include SINE, VNTR and Alu sequences, their presence in genic regions may influence transcription in a manner similar to the above. Observation of neuropeptide-related gene loci revealed SVA insertions in the upstream regions of the tachykinin TACR3 receptor ([Fig. 2](#f0010){ref-type="fig"}a), the oxytocin encoding OXT ([Fig. 2](#f0010){ref-type="fig"}b), and between the cation channel TRPV1 and TRPV3 genes ([Fig. 2](#f0010){ref-type="fig"}c), with the latter having an extensive literature on modulation of neuropeptide function and release. Both TACR3 and OXT have a chimp- and human-specific SVA B beginning less than 3 kb and 8 kb upstream of their respective promoters, which may have conferred distinct regulation of tachykinin receptor 3 and oxytocin in humans and chimpanzees. Vanilloid receptors such as TRPV1 and TRPV3 are also of interest in understanding neuropeptide function, as their activation leads to release of substance P, therefore demonstrating a close relationship between the two systems in many areas of neuronal signalling ([@bb0135]). The TRPV1/V3 genes are separated by approximately 8 kb between the 5′ end of TRPV3 and the 3′ end of TRPV1, and this region contains a human-specific SVA D. The SVA at this locus is less than 6 kb upstream of the TRPV3 transcriptional start site, and immediately adjacent to the end of TRPV1, thus allowing it to potentially modulate the expression of both genes. In a similar manner, the SVA upstream of the OXT gene could potentially regulate the nearby AVP gene at this locus. We hypothesise that these hominid-specific retrotransposons would therefore impart specific regulatory properties upon these genes that may allow for evolutionary changes in their tissue-specific or stimulus inducible regulation.Fig. 2Schematic of the TACR3, OXT, and TRPV1/V3 genes, displaying the positions and evolutionary conservation of SVAs at these loci. (a) The TACR3 gene has a human- and chimp-specific SVA B beginning less than 3 kb upstream of the transcriptional start site. (b) Similarly, a human- and chimp- specific SVA B lies less than 8 kb upstream of the OXT transcriptional start site. (c) Finally, a human-specific SVA D is present within the intervening 8 kb of sequence separating the TRPV1 and TRPV3 genes, with the SVA residing approximately 6 kb upstream of TRPV3 and directly adjacent to the 3′ end of TRPV1. We hypothesise that insertion of SVAs at these loci may have altered regulation of neuropeptide related gene expression during hominid evolution.Fig. 2

4. The polymorphic nature of SVAs {#s0020}
=================================

SVAs are considered to be the most polymorphic elements in the human genome, not just in structure but also for their presence or absence ([@bb0020]). Although mobile genetic elements are often stringently repressed to prevent deleterious changes to the cell\'s genome through further mobilisation and insertion ([@bb0260]), active retrotransposition is known to occur during normal differentiation of neuronal stem cells, and in adult neurogenesis ([@bb0045], [@bb0180]). As such, many of our brain cells contain unique retrotransposon insertions. Although the exact rate is currently an area of controversy ([@bb0240], [@bb0105], [@bb0070]), all groups agree that active mobilisation of retrotransposons occurs in the brain. Higher estimates suggest that each hippocampal neuron contains approximately 13.7 new somatic LINE-1 insertions on average, which are highly enriched at brain-related gene loci ([@bb0240]), however differences in the estimated rates may result from differing sensitivities of the techniques used, and may also differ by cell type.

The SVA structure itself is composed of multiple repetitive domains, each of which may contribute to polymorphic variation in the SVA due to differences in copy number. Within the aforementioned PARK7 SVA, we identified three common variants of the CCCTCT hexamer VNTR, with 7, 10, or 13 copies of the repeat. Similarly, we have shown variation in length in the terminal poly-A stretch in other retrotransposable elements ([@bb0185]). However, the most likely region for copy number variation is the large central VNTR domain, which we have shown to be polymorphic in both the PARK7 SVA and the FUS SVA. We identified three distinct alleles of the central VNTR in the PARK7 SVA and two alleles in the FUS SVA ([@bb0210], [@bb0215]).

5. Summary {#s0025}
==========

Overall, our work suggests that SVA elements can alter gene expression through their capacity for local transcriptional and epigenetic modulation. We hypothesise that SVA insertions at the OXT/AVP, TACR3, and TRPV1/V3 loci, all genes discussed at the Aberdeen Neuropeptide Conference 2015, have contributed to the evolution of species-specific regulation and expression of these genes in humans and other primates, allowing the evolution of higher cognitive and social functioning, as well as variation at these loci acting in combination with our environment to modulate human behaviour. Their high GC content may allow them to act through a similar mechanism to CpG islands, altering the transcriptional availability of a locus depending on epigenetic markers across the element, as demonstrated for the Alu retrotransposon in the POMC gene. Similarly, their high G content means that SVAs have the potential to form alternative DNA structures such as G-quadruplex, which is known to alter transcription and facilitate enhancer-promoter interactions to regulate gene expression across a locus. Variation within SVA elements also provides an additional mechanism to drive differential gene expression through allele-specific transcription factor binding and identifies them as potential biomarkers for disease. The presence of SVAs at neuropeptide gene loci points to a retrotransposon-mediated evolutionary mechanism which may have contributed to the development of human behavioural traits.
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